Liposomal formulations in clinical use: An updated review

Pharmaceutics

Volumn 9, Issue 2, 2017, Pages

  Bulbake, Upendra ^a   Doppalapudi, Sindhu ^a   Kommineni, Nagavendra ^a   Khan, Wahid ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Clinical trials; Drug delivery; Liposome technology; Liposomes; Marketed products; Nanotechnology; Therapeutics

Indexed keywords

AMPHOTERICIN B; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIERUCOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYL PHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIOLEOLY SN GLYCERO PHOPHOETHANOLAMINE; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLSERINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DISTEAROYL SN GLYCERO PHOSPHOETHANOLAMINE; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; EGG PHOSPHATIDYLCHOLINE; FLUOROURACIL; FOLINIC ACID; HYDROGENATED SOY PHOSPHATIDYLCHOLINE; IRINOTECAN; LIPOSOME; MACROGOL; METHOXY POLYETHYLENE GLYCOL; MIFAMURTIDE; MORPHINE SULFATE; PALMITOYLOLEOYLPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SPHINGOMYELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGENICITY; CARDIOTOXICITY; CHEMICAL REACTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; KAPOSI SARCOMA; LIPOSOMAL FORMULATION; LYSOLIPID THERMALLY SENSITIVE LIPOSOME TECHNOLOGY; MENINGITIS; METASTASIS; METASTATIC BREAST CANCER; MULTIPLE MYELOMA; MYCOSIS; NANOTECHNOLOGY; NEOPLASM; NON PEGYATED LIPOSOME TECHNOLOGY; OSTEOSARCOMA; OVARY CANCER; PAIN; PANCREAS ADENOCARCINOMA; PEGYLATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STEALTH LIPOSOME TECHNOLOGY; THERAPEUTIC INDEX;

EID: 85018516576     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics9020012     Document Type: Review

References (154)

1. Bangham, A.; Standish, M.M.; Watkins, J. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13, 238–252.
2. Torchilin, V.; Weissig, V. Liposomes: A Practical Approach; Oxford University Press: Kettering, UK, 2003; pp. 77–101.
3. Barenholz, Y.C. Doxil®—The first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 117–134.
4. Veronese, F.M.; Harris, J.M. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. 2002, 54, 453.
5. Leonard, R.; Williams, S.; Tulpule, A.; Levine, A.; Oliveros, S. Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™). Breast 2009, 18, 218–224.
6. Murry, D.J.; Blaney, S.M. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother. 2000, 34, 1173–1178.
7. Slingerland, M.; Guchelaar, H.-J.; Gelderblom, H. Liposomal drug formulations in cancer therapy: 15 Years along the road. Drug Discov. Today 2012, 17, 160–166.
8. Working, P.; Dayan, A. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol. 1996, 15, 751.
9. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin. Pharmacokinet. 2003, 42, 419–436.
10. Barenholz, Y. Liposome application: Problems and prospects. Curr. Opin. Colloid interface Sci. 2001, 6, 66–77.
11. Barenholz, Y.; Haran, G. Efficient Loading and Controlled Release of Amphipathic Molecules. U.S. Patent No. 5, 316, 771, 31 May 1994.
12. Lasic, D.; Frederik, P.; Stuart, M.; Barenholz, Y.; McIntosh, T. Gelation of liposome interior A novel method for drug encapsulation. FEBS Lett. 1992, 312, 255–258.
13. Lasic, D.; Ceh, B.; Stuart, M.; Guo, L.; Frederik, P.; Barenholz, Y. Transmembrane gradient driven phase transitions within vesicles: Lessons for drug delivery. Biochim. Biophys. Acta (BBA) Biomembr. 1995, 1239, 145–156.
14. Gabizon, A.A. Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 1995, 16, 285–294.
15. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54, 987–992.
16. Batist, G. Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol. 2007, 7, 72–74.
17. Petre, C.E.; Dittmer, D.P. Liposomal daunorubicin as treatment for Kaposi’s sarcoma. Int. J. Nanomed. 2007, 2, 277.
18. Allen, T.M.; Martin, F.J. Advantages of liposomal delivery systems for anthracyclines. In Seminars in Oncology; Elsevier: Amsterdam, The Netherlands, 2004.
19. Forssen, E.A.; Ross, M.E. Daunoxome® treatment of solid tumors: Preclinical and clinical investigations. J. Liposome Res. 1994, 4, 481–512.
20. Forssen, E.A.; Coulter, D.M.; Proffitt, R.T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992, 52, 3255–3261.
21. Gill, P.S.; Espina, B.M.; Muggia, F.; Cabriales, S.; Tulpule, A.; Esplin, J.A.; Liebman, H.A.; Forssen, E.; Ross, M.E.; Levine, A.M. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 1995, 13, 996–1003.
22. Fumagalli, L.; Zucchetti, M.; Parisi, I.; Viganò, M.G.; Zecca, B.; Careddu, A.; D’Incalci, M.; Lazzarin, A. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi’s sarcoma. Cancer Chemother. Pharmacol. 2000, 45, 495–501.
23. Alberts, D.S.; Bachur, N.R.; Holtzman, J.L. The pharmacokinetics of daunomycin in man. Clin. Pharmacol. Ther. 1971, 12, 96–104.
24. Chamberlain, M.C.; Kormanik, P.; Howell, S.B.; Kim, S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch. Neurol. 1995, 52, 912–917.
25. Kim, S.; Chatelut, E.; Kim, J.C.; Howell, S.B.; Cates, C.; Kormanik, P.A.; Chamberlain, M.C. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J. Clin. Oncol. 1993, 11, 2186–2193.
26. Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999, 5, 3394–3402.
27. Balazsovits, J.; Mayer, L.; Bally, M.; Cullis, P.; McDonell, M.; Ginsberg, R.; Falk, R. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 1989, 23, 81–86.
28. Kanter, P.; Bullard, G.; Pilkiewicz, F.; Mayer, L.; Cullis, P.; Pavelic, Z. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 1992, 7, 85–95.
29. Sparano, J.A.; Winer, E.P. Liposomal anthracyclines for breast cancer. In Seminars in Oncology; Elsevier: Amsterdam, The Netherlands, 2001.
30. Cowens, J.; Creaven, P.; Greco, W.; Brenner, D.; Tung, Y.; Ostro, M.; Pilkiewicz, F.; Ginsberg, R.; Petrelli, N. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993, 53, 2796–2802.
31. Harasym, T.O.; Cullis, P.R.; Bally, M.B. Intratumor distribution of doxorubicin following iv administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol. 1997, 40, 309–317.
32. Harris, L.; Batist, G.; Belt, R.; Rovira, D.; Navari, R.; Azarnia, N.; Welles, L.; Winer, E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94, 25–36.
33. Batist, G.; Ramakrishnan, G.; Rao, C.S.; Chandrasekharan, A.; Gutheil, J.; Guthrie, T.; Shah, P.; Khojasteh, A.; Nair, M.K.; Hoelzer, K. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001, 19, 1444–1454.
34. Alphandéry, E.; Grand-Dewyse, P.; Lefèvre, R.; Mandawala, C.; Durand-Dubief, M. Cancer therapy using nanoformulated substances: Scientific, regulatory and financial aspects. Expert Rev. Anticancer ther. 2015, 15, 1233–1255.
35. Vail, D.M.; MacEwen, E.G.; Kurzman, I.D.; Dubielzig, R.R.; Helfand, S.C.; Kisseberth, W.C.; London, C.A.; Obradovich, J.E.; Madewell, B.R.; Rodriguez, C.O. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: A randomized multi-institutional clinical trial. Clin. Cancer Res. 1995, 1, 1165–1170.
36. Anderson, P.; Tomaras, M.; McConnell, K. Mifamurtide in osteosarcoma—A practical review. Drugs Today 2010, 46, 327–337.
37. Anderson, P.; Meyers, P.; Kleinerman, E.; Oliva, C.; Liu, Y. Mifamurtide (L-MTP-PE) for metastatic and recurrent osteosarcoma (OS): Survival and safety profile from a patient access study. In Annals of Oncology; Oxford University Press: Oxford, UK, 2012.
38. Meyers, P.A.; Schwartz, C.L.; Krailo, M.D.; Healey, J.H.; Bernstein, M.L.; Betcher, D.; Ferguson, W.S.; Gebhardt, M.C.; Goorin, A.M.; Harris, M. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival—A report from the Children’s Oncology Group. J. Clin. Oncol. 2008, 26, 633–638.
39. Webb, M.; Harasym, T.; Masin, D.; Bally, M.; Mayer, L. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 1995, 72, 896.
40. Johnston, M.J.; Semple, S.C.; Klimuk, S.K.; Edwards, K.; Eisenhardt, M.L.; Leng, E.C.; Karlsson, G.; Yanko, D.; Cullis, P.R. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim. Biophys.Acta (BBA) Biomembr. 2006, 1758, 55–64.
41. Krishna, R.; Webb, M.S.; Onge, G.S.; Mayer, L.D. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther. 2001, 298, 1206–1212.
42. Rodriguez, M.; Pytlik, R.; Kozak, T.; Chhanabhai, M.; Gascoyne, R.; Lu, B.; Deitcher, S.R.; Winter, J.N. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. Cancer 2009, 115, 3475–3482.
43. Drummond, D.C.; Noble, C.O.; Guo, Z.; Hong, K.; Park, J.W.; Kirpotin, D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006, 66, 3271–3277.
44. Hong, K.; Drummond, D.C.; Kirpotin, D. Liposomes Useful for Drug Delivery. U.S. Patent No. US20160030341 A1, 4 February 2016.
45. Wang-Gillam, A.; Li, C.-P.; Bodoky, G.; Dean, A.; Shan, Y.-S.; Jameson, G.; Macarulla, T.; Lee, K.-H.; Cunningham, D.; Blanc, J.F. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016, 387, 545–557.
46. Lister, J. Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mycoses: The North American experience. Eur. J. Haematol. 1996, 56, 18–23.
47. Madden, T.; Janoff, A.; Cullis, P. Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol. Chem. Phys. Lipids 1990, 52, 189–198.
48. Janoff, A.; Boni, L.; Popescu, M.; Minchey, S.; Cullis, P.R.; Madden, T.; Taraschi, T.; Gruner, S.; Shyamsunder, E.; Tate, M. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 1988, 85, 6122–6126.
49. Olsen, S.J.; Swerdel, M.R.; Blue, B.; Clark, J.M.; Bonner, D.P. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 1991, 43, 831–835.
50. Janoff, A.; Perkins, W.; Saletan, S.; Swenson, C. Amphotericin B lipid complex (ABLC™): A molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. 1993, 3, 451–471.
51. Adedoyin, A.; Bernardo, J.F.; Swenson, C.E.; Bolsack, L.E.; Horwith, G.; DeWit, S.; Kelly, E.; Klasterksy, J.; Sculier, J.-P.; DeValeriola, D. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies. Antimicrob. Agents Chemother. 1997, 41, 2201–2208.
52. Adler-Moore, J.P.; Proffitt, R.T. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 1993, 3, 429–450.
53. Woodle, M.C.; Storm, G. Long Circulating Liposomes: Old Drugs, New Therapeutics; Springer Science & Business Media: Berlin, Germany, 1998.
54. Walsh, T.J.; Yeldandi, V.; McEvoy, M.; Gonzalez, C.; Chanock, S.; Freifeld, A.; Seibel, N.I.; Whitcomb, P.O.; Jarosinski, P.; Boswell, G. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 1998, 42, 2391–2398.
55. Boswell, G.; Buell, D.; Bekersky, I. AmBisome (liposomal amphotericin B): A comparative review. J. Clin. Pharmacol. 1998, 38, 583–592.
56. Guo, L.S.; Fielding, R.M.; Lasic, D.D.; Hamilton, R.L.; Mufson, D. Novel antifungal drug delivery: Stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 1991, 75, 45–54.
57. Fielding, R.; Singer, A.; Wang, L.; Babbar, S.; Guo, L. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 1992, 36, 299–307.
58. Wang, L.H.; Fielding, R.M.; Smith, P.C.; Guo, L.S. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil®) and Fungizone® after repeated dosing in rats. Pharm. Res. 1995, 12, 275–283.
59. Sanders, S.W.; Buchi, K.; Goddard, M.; Lang, J.; Tolman, K. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 1991, 35, 1029–1034.
60. White, M.H.; Anaissie, E.J.; Kusne, S.; Wingard, J.R.; Hiemenz, J.W.; Cantor, A.; Gurwith, M.; Mond, C.D.; Mamelok, R.D.; Bowden, R.A. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. 1997, 24, 635–642.
61. Bowden, R.A.; Cays, M.; Gooley, T.; Mamelok, R.D.; van Burik, J.-A. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. 1996, 173, 1208–1215.
62. Strong, H.A.; Levy, J.; Huber, G.; Fsadni, M. Vision through Photodynamic Therapy of the Eye. U.S. Patent No. US5910510 A, 8 June 1999.
63. Richter, A.M.; Waterfield, E.; Jain, A.K.; Canaan, A.J.; Allison, B.A.; Levy, J.G. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem. Photobiol. 1993, 57, 1000–1006.
64. Bressler, N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP report 1. Arch. Ophthalmol. 1999, 117, 1329–1345.
65. Alam, M.; Hartrick, C.T. Extended-Release Epidural Morphine (DepoDur™): An Old Drug with a New Profile. Pain Pract. 2005, 5, 349–353.
66. Hartrick, C.; Manvelian, G. Sustained-Release Epidural Morphine (DepoDur™): A Review. Todays Ther. Trends 2004, 22, 167–180.
67. Kim, T.; Murdande, S.; Gruber, A.; Kim, S. Sustained-release morphine for epidural analgesia in rats. J. Am. Soc. Anesthesiol. 1996, 85, 331–338.
68. Viscusi, E.R.; Kopacz, D.; Hartrick, C.; Martin, G.; Manvelian, G. Single-dose extended-release epidural morphine for pain following hip arthroplasty. Am. J. Ther. 2006, 13, 423–431.
69. Angst, M.S.; Drover, D.R. Pharmacology of drugs formulated with DepoFoam™. Clin. Pharmacokinet. 2006, 45, 1153–1176.
70. Richard, B.M.; Rickert, D.E.; Newton, P.E.; Ott, L.R.; Haan, D.; Brubaker, A.N.; Cole, P.I.; Ross, P.E.; Rebelatto, M.C.; Nelson, K.G. Safety evaluation of EXPAREL (DepoFoam bupivacaine) administered by repeated subcutaneous injection in rabbits and dogs: Species comparison. J. Drug Deliv. 2011.
71. Davidson, E.M.; Barenholz, Y.; Cohen, R.; Haroutiunian, S.; Kagan, L.; Ginosar, Y. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth. Analg. 2010, 110, 1018–1023.
72. Miller, H.; Terem, T.; Kheladze, K.; Mosidze, B. A single administration of depobupivacaine (TM) intraoperatively provides three-day analgesia and reduction in use of rescue opioids in patients undergoing hemorrhoidectomy. In Diseases of the Colon & Rectum; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2009.
73. Clarke, P.D.; Adams, P.; Ibáñez, R.; Herzog, C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med. Infect. Dis. 2006, 4, 313–318.
74. Zylberberg, C.; Matosevic, S. Pharmaceutical liposomal drug delivery: A review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016, 23, 1–11.
75. Bungener, L.; Serre, K.; Bijl, L.; Leserman, L.; Wilschut, J.; Daemen, T.; Machy, P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002, 20, 2287–2295.
76. Ambrosch, F.; Wiedermann, G.; Jonas, S.; Althaus, B.; Finkel, B.; Glück, R.; Herzog, C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15, 1209–1213.
77. Perez, O.M.; Herzog, C.; Zellmeyer, M.; Loáisiga, A.; Frösner, G.; Egger, M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: Randomized placebo-controlled trial. J. Infect. Dis. 2003, 188, 671–677.
78. Bovier, P.; Bock, J.; Loutan, L.; Farinelli, T.; Glueck, R.; Herzog, C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol. 2002, 68, 489–493.
79. Gluck, R.; Metcalfe, I. New technology platforms in the development of vaccines for the future. Vaccine 2002, 20, 10–16.
80. Gluck, R.; Mischler, R.; Finkel, B.; Que, J.; Cryz, S.; Scarpa, B. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994, 344, 160–163.
81. Conne, P.; Gauthey, L.; Vernet, P.; Althaus, B.; Que, J.U.; Finkel, B.; Glück, R.; Cryz, S.J. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997, 15, 1675–1679.
82. Li, Z.; Zhang, Y.; Wurtz, W.; Lee, J.K.; Malinin, V.S.; Durwas-Krishnan, S.; Meers, P.; Perkins, W.R. Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21, 245–254.
83. Clancy, J.P. Clinical trials of lipid-associated aerosolized amikacin: The arikace™ story. In Pediatric Pulmonology; Wiley-Liss Div JohnWiley & Sons Inc.: Hoboken, NJ, USA, 2009.
84. Bilton, D.; Pressler, T.; Fajac, I.; Clancy, J.P.; Sands, D.; Minic, P.; Cipolli, M.; LaRosa, M.; Galeva, I.; Sole, A.A. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (ARIKACE) Compared with TOBI in cystic fibrosis patients with chronic infection due to Pseudomonas Aeruginosa. Pediatr. Pulmonol. 2013, 48, 207–453.
85. Clancy, J.; Dupont, L.; Konstan, M.W.; Billings, J.; Fustik, S.; Goss, C.H.; Lymp, J.; Minic, P.; Quittner, A.; Rubenstein, R. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68, 818–825.
86. Gupta, R.; Daley, C.L.; Winthrop, K.L.; Ruoss, S.; Addrizzo-Harris, D.J.; Flume, P.; Dorgan, D.; Salathe, M.A.; Olivier, B.; Brown-Elliott, A. A randomized, double-blind, placebo-controlled study of liposomal amikacin for inhalation (Arikace®) in patients with recalcitrant nontuberculous mycobacterial lung disease. In C27. Diagnosis and Treatment of Nontuberculous Mycobacteria Infections; American Thoracic Society: New York, NY, USA, 2014; p. 4126.
87. Timmerman, L. Oncothyreon Marches on with ‘Son of Stimuvax’ Cancer Vaccine. Available online: http://www.xconomy.com/seattle/2012/04/10/oncothyreon-marches-on-with-son-of-stimuvaxcancer-vaccine/ (accessed on 27 March 2017).
88. Kroemer, G.; Zitvogel, L.; Galluzzi, L. Victories and deceptions in tumor immunology: Stimuvax®. Oncoimmunology 2013, 2, e23687.
89. Bradbury, P.A.; Shepherd, F.A. Immunotherapy for lung cancer. J. Thorac. Oncol. 2008, 3, S164–S170.
90. Vergati, M.; Intrivici, C.; Huen, N.-Y.; Schlom, J.; Tsang, K.Y. Strategies for cancer vaccine development. BioMed Res. Int. 2010, 2010, 1–13.
91. Cart, S.; Alert, N.P.R. Merck KGaA Starts Stimuvax Phase III Study INSPIRE in Asian Patients with Advanced NSCLC. Available online: http://www.businesswire.com/news/home/20091210005488/en/Merck-KGaAStarts-Stimuvax-Phase-III-Study (accessed on 27 March 2017).
92. Zahid, S.; Brownell, I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J. Drugs Dermatol. 2008, 7, 405–408.
93. Yarosh, D.B.; Kibitel, J.T.; Green, L.A.; Spinowitz, A. Enhanced unscheduled DNA synthesis in UV-irradiated human skin explants treated with T4N5 liposomes. J. Investig. Dermatol. 1991, 97, 147–150.
94. Wolf, P.; Müllegger, R.R.; Soyer, H.P.; Hofer, A.; Smolle, J.; Horn, M.; Cerroni, L.; Hofmann-Wellenhof, R.; Kerl, H.; Maier, H. Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factory. J. Investig. Dermatol. 2000, 114, 149–156.
95. Cafardi, J.A.; Elmets, C.A. T4 endonuclease V: Review and application to dermatology. Expert Opin. Biol. Ther. 2008, 8, 829–838.
96. Chang, H.-I.; Yeh, M.-K. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int. J. Nanomed. 2012, 7, 49–60.
97. Summers, D.; Ruff, D.; Smalling, R.; Cardoza, D.; Dottavio, D.; Lasic, D. Administration of liprostin (TM) for the treatment of critical limb ischemia (CLI) and peripheral arterial disease (PAD). In Journal of Liposome Research; Marcel Dekker Inc.: New York, NY, USA, 2003.
98. Li, J.; Wang, B.; Wang, Y.; Wu, F.; Li, P.; Li, Y.; Zhao, L.; Cui, W.; Ding, Y.; An, Q. Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures. Exp. Ther. Med. 2013, 5, 1760–1764.
99. Chen, J.; He, C.-Q.; Lin, A.-H.; Gu, W.; Chen, Z.-P.; Li, W.; Cai, B.-C. Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor. Int. J. Pharm. 2014, 475, 408–415.
100. Mylonopouloua, E.; Arvanitisa, C.D.; Bazan-Peregrinoa, M.; Arora, M.; Coussios, C.C. Ultrasonic activation of thermally sensitive liposomes. In Proceedings of the 9th International Symposium on Therapeutic Ultrasound: Istu—2009, Aix-en-Provence, France, 24–26 September 2009; AIP Publishing: New York, NY, USA, 2010.
101. Puri, A. Phototriggerable liposomes: Current research and future perspectives. Pharmaceutics 2013, 6, 1–25.
102. Wood, B.; Poon, R.; Neeman, Z.; Eugeni, M.; Locklin, J.; Dromi, S.; Kachala, S.; Probhakar, R.; Hahne, W.; Libutti, S. Phase I study of thermally sensitive liposomes containing doxorubicin (ThermoDox) given during radiofrequency ablation (RFA) in patients with unresectable hepatic malignancies. In Proceedings of the Gastrointestinal Cancers Symposium, Orlando, FL, USA, 19–21 January 2007; The American Society of Clinical Oncology: Alexandria, VA, USA, 2007.
103. Dromi, S.; Quijano, J.; Xie, J.; Frenkel, V.; Wood, B.; Li, K. Pulsed-high intensity focused ultrasound (HIFU) enhanced delivery of Doxorubicin using heat sensitive liposome (Thermodox TM). In Proceedings of the 91st Annual Meeting of the Radiological Society of North America, Chicago, IL, USA, 27 November–2 December 2005.
104. Palazzi, M.; Maluta, S.; Dall’Oglio, S.; Romano, M. The role of hyperthermia in the battle against cancer. Tumori 2010, 96, 902.
105. Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12, 991–1003.
106. Egusquiaguirre, S.P.; Igartua, M.; Hernández, R.M.; Pedraz, J.L. Nanoparticle delivery systems for cancer therapy: Advances in clinical and preclinical research. Clin. Transl. Onco. 2012, 14, 83–93.
107. Boulikas, T. Clinical overview on Lipoplatin™: A successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs 2009, 18, 1197–1218.
108. Sotiriosrigatos, E.D.; Viliotou, V.; Stathopoulos, J.G. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study. Oncol. Rep. 2005, 13, 589–595.
109. Stathopoulos, G.P.; Boulikas, T.; Vougiouka, M.; Rigatos, S.K.; Stathopoulos, J.G. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncol. Rep. 2006, 15, 1201–1204.
110. Mylonakis, N.; Athanasiou, A.; Ziras, N.; Angel, J.; Rapti, A.; Lampaki, S.; Politis, N.; Karanikas, C.; Kosmas, C. Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010, 68, 240–247.
111. Boulikas, T.; Stathopoulos, G.P.; Volakakis, N.; Vougiouka, M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 2005, 25, 3031–3039.
112. Harper, B.W.; Krause-Heuer, A.M.; Grant, M.P.; Manohar, M.; Garbutcheon-Singh, K.B.; Aldrich-Wright, J.R. Advances in platinum chemotherapeutics. Chem. Eur. J. 2010, 16, 7064–7077.
113. Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1, 297.
114. Farrell, N.P. Platinum formulations as anticancer drugs clinical and pre-clinical studies. Curr. Top. Med. Chem. 2011, 11, 2623–2631.
115. Dragovich, T.; Mendelson, D.; Hoos, A.; Lewis, J.; Kurtin, S.; Richardson, K.; von Hoff, D. 268 A phase II trial of aroplatin (L-NDDP), a liposomal DACH platinum, in patients with metastatic colorectal cancer (CRC)-a preliminary report. Eur. J. Cancer Suppl. 2003, 1, S82–S83.
116. Jakupec, M.; Galanski, M.; Keppler, B. Tumour-inhibiting platinum complexes—State of the art and future perspectives. In Reviews of physiology, Biochemistry and Pharmacology; Springer: New York, NY, USA, 2003; pp. 1–53.
117. Zou, Y.; Priebe, W.; Perez-Soler, R. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: Effect of surfactant on liposome formation, stability and size. Cancer Chemother. Pharmacol. 1996, 39, 103–108.
118. Wasan, K.M.; Perez-Soler, R. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J. Pharm. Sci. 1995, 84, 1094–1100.
119. Zou, Y.; Ling, Y.H.; Van, N.T.; Priebe, W.; Perez-Soler, R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. 1994, 54, 1479–1484.
120. Pui, C.-H.; Jeha, S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat. Rev. Drug Discov. 2007, 6, 149–165.
121. Wetzler, M.; Thomas, D.A.; Wang, E.S.; Shepard, R.; Ford, L.A.; Heffner, T.L.; Parekh, S.; Andreeff, M.; O’Brien, S.; Kantarjian, H.M. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 2013, 13, 430–434.
122. Harrington, K.J.; Rowlinson-Busza, G.; Syrigos, K.N.; Vile, R.G.; Uster, P.S.; Peters, A.M.; Stewart, J.S.W. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin. Cancer Res. 2000, 6, 4939–4949.
123. Zamboni, W.C.; Gervais, A.C.; Egorin, M.J.; Schellens, J.H.; Zuhowski, E.G.; Pluim, D.; Joseph, E.; Hamburger, D.R.; Working, P.K.; Colbern, G. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother. Pharmacol. 2004, 53, 329–336.
124. Tomkinson, B.; Bendele, R.; Giles, F.J.; Brown, E.; Gray, A.; Hart, K.; LeRay, J.D.; Meyer, D.; Pelanne, M.; Emerson, D.L. OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leuk. Res. 2003, 27, 1039–1050.
125. Yu, N.Y.; Conway, C.; Pena, R.L.; Chen, J.Y. STEALTH® liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res. 2007, 27, 2541–2545.
126. Zamboni, W.C.; Strychor, S.; Joseph, E.; Walsh, D.R.; Zamboni, B.A.; Parise, R.A.; Tonda, M.E.; Ning, Y.Y.; Engbers, C.; Eiseman, J.L. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin. Cancer Res. 2007, 13, 7217–7223.
127. Zhang, J.A.; Xuan, T.; Parmar, M.; Ma, L.; Ugwu, S.; Ali, S.; Ahmad, I. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 2004, 270, 93–107.
128. Gupta, V.; Su, Y.S.; Samuelson, C.G.; Liebes, L.F.; Chamberlain, M.C.; Hofman, F.M.; Schönthal, A.H.; Chen, T.C. Irinotecan: A potential new chemotherapeutic agent for atypical or malignant meningiomas. J. Neurosurg. 2007, 106, 455–462.
129. Maroun, J.; Jonker, D.; Seymour, L.; Goel, R.; Vincent, M.; Kocha, W.; Cripps, C.; Fisher, B.; Lister, D.; Malpage, A. A National Cancer Institute of Canada Clinical Trials Group Study–IND. 135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. Eur. J. Cancer 2006, 42, 193–199.
130. Zhang, J.A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 2005, 59, 177–187.
131. Tan, A.; Hanauske, A.; Gelderblom, H.; Scheulen, M.; vanWarmerdam, L.; Rosing, H.; Fetterly, G.; Shu, V.; Sherman, J.; Rubin, E. Results of a clinical pharmacokinetic (PK) bioequiulence (BE) study of liposomal paclitaxel (LEP-ETU) versus paclitaxel (T) in patients with advanced cancer. In Journal of Clinical Oncology; American Society of Clinical Oncology: Alexandria, VA, USA, 2006.
132. Slingerland, M.; Guchelaar, H.-J.; Rosing, H.; Scheulen, M.E.; van Warmerdam, L.J.; Beijnen, J.H.; Gelderblom, H. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: A randomized, two-period crossover study in patients with advanced cancer. Clin. Ther. 2013, 35, 1946–1954.
133. Eichhorn, M.E.; Ischenko, I.; Luedemann, S.; Strieth, S.; Papyan, A.; Werner, A.; Bohnenkamp, H.; Guenzi, E.; Preissler, G.; Michaelis, U. Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int. J. Cancer 2010, 126, 1235–1245.
134. Schuch, G. EndoTAG-1. MediGene. Curr. Opin. Investig. Drugs 2005, 6, 1259.
135. Lohr, M.; Haas, S.; Bechstein, W.; Bodoky, G.; Maerten, A.; Fischbach, W.; Lilla, C.; Mescheder, A.; Pap, A.; Fölsch, U. A phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patients with unresectable pancreatic cancer. In Proceedings of the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 15–17 January 2009.
136. Wallace, T.L.; Larson, J.L.; Bazemore, S.A.; Wilson, C.W.; Cossum, P.A. The nonclinical safety evaluation of the anticancer drug ATRAGEN® (Liposomal all-trans-retinoic acid). Int. J. Toxicol. 2000, 19, 33–42.
137. Douer, D.; Estey, E.; Santillana, S.; Bennett, J.M.; Lopez-Bernstein, G.; Boehm, K.; Williams, T. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-transretinoic acid. Blood 2001, 97, 73–80.
138. Dutta, R.C. Drug carriers in pharmaceutical design: Promises and progress. Curr. Pharm. Des. 2007, 13, 761–769.
139. Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J. Control. Release 2015, 200, 138–157.
140. Ahmad, A.; Wang, Y.-F.; Ahmad, I. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: Pharmacokinetics in mice. Methods Enzymol. 2005, 391, 176–185.
141. Tayi, W.; Cheng, K. Advanced drug delivery in cancer therapy. In Advanced Drug Delivery; Mitra, C.H.L.A., Cheng, K., Eds.; JohnWiley & Sons: Hoboken, NJ, USA, 2013.
142. Tari, A.M.; Gutiérrez-Puente, Y.; Monaco, G.; Stephens, C.; Sun, T.; Rosenblum, M.; Belmont, J.; Arlinghaus, R.; Lopez-Berestein, G. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int. J. Oncol. 2007, 31, 1243–1250.
143. Ashizawa, A.T.; Cortes, J. Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100–1.01. Expert Opin. Drug deliv. 2015, 12, 1107–1120.
144. Ohanian, M.; Kantarjian, H.M.; Ravandi, F.; Borthakur, G.; Garcia-Manero, G.; Andreeff, M.; Jabbour, E.; Konopleva, M.; Lim, M.; Pierce, S. Safety, Pharmacokinetics, and Efficacy of BP-100–1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 2015, 126, 3801–3801.
145. Singh, R.; Kumari, P.; Kumar, S. Nanotechnology for enhanced bioactivity of bioactive phytomolecules. In Nutrient Delivery; Grumezescu, A.M., Ed.; Elsevier: Amsterdam, The Netherlands, 2016.
146. Torchilin, V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13, 813–827.
147. Egusquiaguirre, S.P.; Pedraz, J.L.; Hernandez, R.M.; Igartua, M. Nanotherapeutic platforms for cancer treatment: From preclinical development to clinical application. In Nanoarchitectonics for Smart Delivery and Drug Targeting; Grumezescu, A., Holban, A.M., Eds.; Elsevier: Amsterdam, The Netherlands, 2016; pp. 813–869.
148. Lee, J.-M.; Yoon, T.-J.; Cho, Y.-S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed Res. Int. 2013.
149. Zuckerman, J.E.; Davis, M.E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 2015, 14, 843–856.
150. Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J.-P.; Passirani, C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34, 6429–6443.
151. Gaillard, P.J.; Appeldoorn, C.C.; Dorland, R.; van Kregten, J.; Manca, F.; Vugts, D.J.; Windhorst, B.; van Dongen, G.A.; de Vries, H.E.; Maussang, D. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione PEGylated liposomal doxorubicin (2B3–101). PLoS ONE 2014, 9, e82331.
152. Gaillard, P.J.; Visser, C.C.; Appeldoorn, C.C.; Rip, J. Enhanced brain drug delivery: Safely crossing the blood–brain barrier. Drug Discov. Today Technol. 2012, 9, e155–e160.
153. Birngruber, T.; Raml, R.; Gladdines, W.; Gatschelhofer, C.; Gander, E.; Ghosh, A.; Kroath, T.; Gaillard, P.J.; Pieber, T.R.; Sinner, F. Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx, ®/Doxil®—A Cerebral Open Flow Microperfusion Pilot Study. J. Pharm. Sci. 2014, 103, 1945–1948.
154. Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 2016, 244, 108–121.